Evommune, Inc. (EVMN)
Data as of , from SEC Form 4 filings.
See up to 3 months of EVMN. The 7-day demo opens the 1M and 3M ranges and puts EVMN on your watchlist.
Start 7-day demoLatest EVMN insider trades
About Evommune, Inc. (EVMN)
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
- PALO ALTO, CA
- 48
- 2025
- XNYS
EVMN Form 4 activity by transaction type, last 90 days
No Form 4 activity for EVMN in the last 90 days.
EVMN insider transactions (Form 4)
6942 Form 4 filings on record, the earliest from Nov 7, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Kyle Carver - Officer | Open-market purchase | Common Stock | 1,000 | $13.26 | $13K | |
| Arthur S. Kirsch | Open-market purchase | Common Stock | 10,000 | $13.30 footnote F1 | $133K | |
| ||||||
| Janice Suzann Drew - Officer | Option exercise | Employee Stock Option (Right to Buy) | 3,839 | $0.00 | - | |
| Janice Suzann Drew - Officer | Option exercise | Employee Stock Option (Right to Buy) | 16,161 | $0.00 | - | |
| Janice Suzann Drew - Officer | Option exercise | Common Stock | 3,839 | $3.84 | $15K | |
| Janice Suzann Drew - Officer | Option exercise | Common Stock | 16,161 | $2.99 | $48K | |
| Janice Suzann Drew - Officer | Open-market sale | Common Stock | 20,000 | $22.63 footnote F2 | $453K | |
| ||||||
| Jeegar Pravinkumar Patel - Officer | Option exercise | Common Stock | 1,488 | $3.84 | $6K | |
| Jeegar Pravinkumar Patel - Officer | Open-market sale | Common Stock | 1,488 | $22.50 | $33K | |
| Jeegar Pravinkumar Patel - Officer | Option exercise | Employee Stock Option (Right to Buy) | 1,488 | $0.00 | - | |
| Luis C. Pena - Officer | Open-market sale | Common Stock | 7,438 | $22.71 footnote F2 | $169K | |
| ||||||
| Benjamin F. McGraw III | Grant or award | Stock Option (Right to buy) | 15,673 | $0.00 | - | |
| Arthur S. Kirsch | Grant or award | Stock Option (Right to buy) | 15,673 | $0.00 | - | |
| David E. Cohen | Open-market sale | Common Stock | 5,456 | $20.21 footnote F2 | $110K | |
| David E. Cohen | Open-market sale | Common Stock | 600 | $21.38 footnote F3 | $13K | |
| David E. Cohen | Grant or award | Stock Option (Right to buy) | 15,673 | $0.00 | - | |
| ||||||
| Jeegar Pravinkumar Patel - Officer | Option exercise | Common Stock | 13,512 | $3.84 | $52K | |
| Jeegar Pravinkumar Patel - Officer | Open-market sale | Common Stock | 16,687 | $22.74 footnote F2 | $379K | |
| Jeegar Pravinkumar Patel - Officer | Option exercise | Employee Stock Option (Right to Buy) | 13,512 | $0.00 | - | |
| ||||||
| Luis C. Pena - Officer | Open-market sale | Common Stock | 16,787 | $22.74 footnote F2 | $382K | |
| ||||||
| Gregory S. Moss - Officer | Option exercise | Common Stock | 14,223 | $1.71 | $24K | |
| Gregory S. Moss - Officer | Open-market sale | Common Stock | 14,223 | $22.83 footnote F2 | $325K | |
| Gregory S. Moss - Officer | Option exercise | Employee Stock Option (Right to Buy) | 14,223 | $0.00 | - | |
| ||||||
| Kyle Carver - Officer | Option exercise | Common Stock | 15,000 | $2.99 | $45K | |
| Kyle Carver - Officer | Open-market sale | Common Stock | 18,175 | $22.84 footnote F2 | $415K | |
| Kyle Carver - Officer | Option exercise | Employee Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| ||||||
| Jeegar Pravinkumar Patel - Officer | Grant or award | Employee Stock Option (Right to Buy) | 69,315 | $0.00 | - | |
| Janice Suzann Drew - Officer | Grant or award | Employee Stock Option (Right to Buy) | 73,892 | $0.00 | - | |
| Eugene Bauer - Officer | Grant or award | Employee Stock Option (Right to Buy) | 51,117 | $0.00 | - | |
| Kyle Carver - Officer | Grant or award | Employee Stock Option (Right to Buy) | 98,946 | $0.00 | - | |
| Gregory S. Moss - Officer | Grant or award | Employee Stock Option (Right to Buy) | 115,279 | $0.00 | - | |
| Luis C. Pena - Officer | Grant or award | Employee Stock Option (Right to Buy) | 291,420 | $0.00 | - | |
| 7. Cooperative Ua Lsp | Grant or award | Common Stock | 358,680 | $27.88 | $10.00M | |
| Weegen Felice Isabel Verduyn-Van | Grant or award | Common Stock | 358,680 | $27.88 | $10.00M | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Common Stock | 35,868 | $27.88 | $1.00M | |
| Robert Lorne Hopfner - Director | Open-market purchase | Common Stock | 1,000 | $17.35 | $17K | |
| Weegen Felice Isabel Verduyn-Van | Open-market purchase | Common Stock | 1,562,500 | $16.00 | $25.00M | |
| Weegen Felice Isabel Verduyn-Van | Other | Series A Preferred Stock | 15,493,466 | - footnote F1 | - | |
| Weegen Felice Isabel Verduyn-Van | Other | Series B Preferred Stock | 5,090,000 | - footnote F2 | - | |
| Weegen Felice Isabel Verduyn-Van | Other | Series C Preferred Stock | 6,585,011 | - footnote F3 | - | |
| Weegen Felice Isabel Verduyn-Van | Other | Common Stock | 3,367,133 | - footnote F1,F2,F3 | - | |
| ||||||
| Jeegar Pravinkumar Patel - Officer | Other | Common Stock | 3,175 | - footnote F1 | - | |
| Jeegar Pravinkumar Patel - Officer | Other | Series B Preferred Stock | 25,000 | - footnote F1 | - | |
| ||||||
| Janice Suzann Drew - Officer | Other | Common Stock | 1,587 | - footnote F1 | - | |
| Janice Suzann Drew - Officer | Other | Series B Preferred Stock | 12,500 | - footnote F1 | - | |
| ||||||
| 7. Cooperative Ua Lsp | Other | Series A Preferred Stock | 15,493,466 | - footnote F1 | - | |
| 7. Cooperative Ua Lsp | Other | Series B Preferred Stock | 5,090,000 | - footnote F2 | - | |
| 7. Cooperative Ua Lsp | Other | Series C Preferred Stock | 6,585,011 | - footnote F3 | - | |
| 7. Cooperative Ua Lsp | Other | Common Stock | 3,367,133 | - footnote F1,F2,F3 | - | |
| 7. Cooperative Ua Lsp | Open-market purchase | Common Stock | 1,562,500 | $16.00 | $25.00M | |
| ||||||
| Kyle Carver - Officer | Other | Common Stock | 3,175 | - footnote F1 | - | |
| Kyle Carver - Officer | Other | Series B Preferred Stock | 25,000 | - footnote F1 | - | |
| ||||||
| Gregory S. Moss - Officer | Other | Common Stock | 3,175 | - footnote F1 | - | |
| Gregory S. Moss - Officer | Other | Series B Preferred Stock | 25,000 | - footnote F1 | - | |
| ||||||
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Common Stock | 1,632,441 | - footnote F1,F2,F3,F4 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Common Stock | 294,502 | - footnote F4 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series Seed Preferred Stock | 7,145,647 | - footnote F1 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series Seed Preferred Stock | 3,572,816 | - footnote F1 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series A Preferred Stock | 2,582,243 | - footnote F2 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series A Preferred Stock | 7,230,283 | - footnote F2 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series B Preferred Stock | 1,895,260 | - footnote F3 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series B Preferred Stock | 2,104,740 | - footnote F3 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series C Preferred Stock | 313,571 | - footnote F4 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series C Preferred Stock | 313,571 | - footnote F4 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Series C Preferred Stock | 2,508,575 | - footnote F4 | - | |
| Pivotal bioVenture Partners Fund I, L.P. - Director | Other | Common Stock | 1,441,032 | - footnote F1,F2,F3,F4 | - | |
| ||||||
| Eugene Bauer - Officer | Other | Common Stock | 25,812 | - footnote F1,F2 | - | |
| Eugene Bauer - Officer | Other | Series Seed Preferred Stock | 206,355 | - footnote F1 | - | |
| Eugene Bauer - Officer | Other | Series B Preferred Stock | 12,500 | - footnote F2 | - | |
| ||||||
Item 7.01, 9.01
Item 7.01, 9.01
Item 7.01, 9.01
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Recent EVMN Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
EVMN insider trading FAQ
What is the latest insider trade for EVMN?
Evommune, Inc. (EVMN) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-10. The full record for EVMN runs to 42 Form 4 filings, the earliest from 2025-11-07. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying EVMN stock?
No insider purchases of EVMN were filed in the last 90 days. 7 purchases are on record for this company.
How many insiders are selling EVMN stock?
No insider sales of EVMN were filed in the last 90 days. 9 sales are on record for this company.
Where can I see EVMN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects EVMN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Kyle Carver view on EDGAR
- - Arthur S. Kirsch view on EDGAR
- - Janice Suzann Drew view on EDGAR
- - Jeegar Pravinkumar Patel view on EDGAR
- - Luis C. Pena view on EDGAR
- - Benjamin F. McGraw III view on EDGAR
- - Arthur S. Kirsch view on EDGAR
- - David E. Cohen view on EDGAR
- - Jeegar Pravinkumar Patel view on EDGAR
- - Luis C. Pena view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where EVMN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow EVMN with a 7-day demo
- EVMN on your watchlist
- Every EVMN Form 4 filing on record
- Up to 3 months of EVMN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.